posteditor

posteditor

Renibus Therapeutics Announces Oral Presentation on Phase 3 PROTECT Trial Data for RBT-1 at the American Association for Thoracic Surgery (AATS) Annual Meeting

P Clinical study in cardiac surgery patients demonstrates favorable safety profile; exploratory analyses suggest potential benefit in higher-risk populations SOUTHLAKE, Texas, April 30, 2026 /PRNewswire/ — Renibus Therapeutics® (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio,…